Alnylam Pharmaceuticals
ALNY
#612
Rank
A$57.45 B
Marketcap
A$430.59
Share price
-0.81%
Change (1 day)
18.81%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of December 2025 : A$5.83 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are A$5.83 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2025)

Total liabilities by year

Year Total liabilities Change
2025-12-31A$6.23 B-7.04%
2024-12-31A$6.70 B12.84%
2023-12-31A$5.94 B9.21%
2022-12-31A$5.44 B29.18%
2021-12-31A$4.21 B35.53%
2020-12-31A$3.10 B127.61%
2019-12-31A$1.36 B252.72%
2018-12-31A$0.38 B32.44%
2017-12-31A$0.29 B-38.47%
2016-12-31A$0.47 B184.27%
2015-12-31A$0.16 B-4.54%
2014-12-31A$0.17 B4.02%
2013-12-31A$0.16 B14.01%
2012-12-31A$0.14 B-7.62%
2011-12-31A$0.15 B-30.91%
2010-12-31A$0.23 B-31.5%
2009-12-31A$0.33 B-32.41%
2008-12-31A$0.49 B48.29%
2007-12-31A$0.33 B584.1%
2006-12-31A$49.26 M-1.44%
2005-12-31A$49.97 M93.72%
2004-12-31A$25.79 M-69.01%
2003-12-31A$83.26 M126%
2002-12-31A$36.84 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Novartis
NVS
A$89.90 B 1,441.72%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$90.35 B 1,449.42%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$12.98 B 122.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A$3.08 B-47.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A$8.09 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A$0.92 B-84.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$45.83 B 686.04%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$1.45 B-75.07%๐Ÿ‡บ๐Ÿ‡ธ USA